The Future of Longevity with Tony Robbins

Is there a limit to what humans can do? And if so, how do you know when you've reached it? Welcome to part one of a two-part series on human performance with professional rock climber Alex Honnold. Alex redefined the limits of what is possible by free soloing – that is climbing with no ropes or safety gear – a 2000-foot granite rock face in Yosemite, known as El Capitan. That feat  was documented in the award-winning film Free Solo. In this podcast, Alex, a16z general partner Peter Levine (who at age 59 is still an avid ice climber), and Das Rush discuss how technology and training have pushed the limits of what's possible and how to manage the mental preparation of any big endeavor, whether its building a company, reaching a new peak, or maintaining peak performance while aging.In Part 2, recorded last year as part of our a16z innovation summit, we share a fireside chat with Peter and Alex  about the risk, preparation, and fear around Alex's free solo.  Photo credit: Shawn Corrigan

11 Juli 202023min

"Why We Shouldn’t Fear the ‘Black Box’ of AI (in Healthcare and Everywhere)" by Vijay Pande. First published in the New York Times, January 2018. You can also find and share this article at a16z.com/aidoctor

7 Juli 20206min

"When One App Rules Them All: The Case of WeChat and Mobile in China" by Connie Chan. First published August 2015. You can also find and share this essay at a16z.com/mobilefirstchina

7 Juli 202020min

"Why Every Company Will Be a Fintech Company -- The Next Era of Financial Services and the 'AWS Phase' for Fintech" by Angela Strange.You can also find and share this essay at a16z.com/fintecheverywhere

7 Juli 202015min

Today we're continuing a series we started a while ago of read-alouds (for more context on the why and why now check out episode #500 on how we podcast!).The first was episode #544 in April, It's Time to Build, read out loud by Marc Andreessen; what follows are  three more pieces read out loud by their authors:"Why Every Company Will Become a Fintech Company: The Next Era of Financial Services and the 'AWS Phase' for Fintech" by Angela Strange"When One App Rules Them All: The Case of WeChat and Mobile in China" by Connie Chan, first published August 2015"Why We Shouldn’t Fear the ‘Black Box’ of AI (in Healthcare and Everywhere)" by Vijay Pande, first published in the New York Times January 2018

7 Juli 202051s

Eroom’s Law is Moore’s Law spelled backwards. It’s a term that was coined in a Nature Reviews Drug Discovery article by researchers at Sanford Bernstein and describes the exponential decrease in biopharma research and development efficiency between the 1950s and 2010. Whereas Moore’s describes technologies becoming exponentially faster and cheaper over time, Eroom’s Law describes the trend of drug development becoming exponentially more expensive over time.The article describing Eroom’s Law was published in 2012, and analyzed data up till 2010. That is perhaps ironic as 2010 appears to be an inflection point in the trend. In Breaking Eroom’s Law, the authors analyze the data since 2010 and show that costs appear to have stabilized over the last ten years. But what has contributed to this critical and exciting trend shift? In our conversation, Jorge and Vijay discuss the three causes cited by the authors of the Breaking Eroom’s Law article, their views on what technologies and policies will continue to push costs down, and their opinion on whether Eroom’s Law is broken for good.

5 Juli 20209min

The COVID-19 pandemic has increased the visibility of scientists and the scientific process to the broader public; suddenly, scientists working on virology and infectious disease dynamics have seen their public profiles rapidly expand. One such scientist is the special guest in this episode, Trevor Bedford, Associate Professor at the Fred Hutchinson Cancer Research Center.An expert in genomic epidemiology, he and his collaborators built Nextstrain, which shares real-time, interactive data visualizations to track the spread of viruses through populations.a16z bio deal team partner Judy Savitskaya and Lauren Richardson chat with Trevor about how genomic epidemiology can inform public health decisions; viral mutation and spillover from animals into humans; what can be done now to prevent the next big pandemic; and the shift in scientific communication to pre-prints and open science.

30 Juni 202034min

In this episode of the a16z bio journal club, we cover one of the key clinical trials that supported the recent FDA approval of the first prescription video game. The game was developed by Akili Interactive, is called EndeavorRx, and is now a clinically-validated therapy for improving attention in children with Attention Deficit Hyperactivity Disorder (ADHD). But how does a game improve attention? How does a clinical trial evaluate the efficacy of a game? And what are the pros and cons of a video game as compared to traditional pharmacological therapies for ADHD? Bio deal team partner Justin Larkin and Lauren Richardson delve into these questions and more in their discussion of this clinical trial:“A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial” in Lancet Digital Health (April 2020) by Scott H Kollins, Denton J DeLoss, Elena Cañadas, Jacqueline Lutz, Robert L Findling, Richard S E Keefe, Jeffery N Epstein, Andrew J Cutler, and Stephen V Faraone.a16z bio Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature -- what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.

28 Juni 202017min